A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005905/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
提供机构：
Vivli
创建时间：
2020-06-08
